MedImmune, Abpro form research venture | Chemical & Engineering News
Volume 94 Issue 48 | p. 15 | Concentrates
Issue Date: December 5, 2016

MedImmune, Abpro form research venture

Department: Business
Keywords: pharmaceuticals, antibodies, spin-out

MedImmune, the biologics division of AstraZeneca, and Abpro, a synthetic biology specialist, are collaborating in a spin-off company, AbMed, that will develop antibodies targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). AbMed will operate as a subsidiary of Abpro, which will receive development and commercialization rights to research programs. MedImmune will receive development, regulatory, and sales milestone and royalty payments. MedImmune will also take a minority equity stake in AbMed.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment